الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 155 |  |  |
| | | from | 155 | | |
Abstract
CXCL13 is a B-cell chemokine produced mainly by mesenchymal lymphoid tissue organizer cells, follicular dendritic cells, and human T follicular helper cells. By binding to its receptor, CXCR5, CXCL13 plays an important role in lymphoid neogenesis, lymphoid organization, and immune responses.
Recent studies have found that CXCL13 and its receptor CXCR5 are implicated in the pathogenesis of several autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, primary Sjögren’s syndrome, myasthenia gravis, and inflammatory bowel disease.
Nevertheless, the role of CXCL13 has not yet been investigated in vitiligo. Therefore, the aim of this current study was to evaluate the role of CXCL13 in the immune pathogenesis of vitiligo among patients attending the Suez Canal University Hospitals, through a case control study conducted upon 42 participants: 21 patients and 21 healthy controls.
Most of our participants were females and the majority of the patients aged more than 40 years, while most of the controls aged from 20 to 40 years. Most of the patients reported that the age of onset of the disease was more than 20 years ago.
One of the primary objectives of this current study was to assess difference in the serum level of CXCL13 among vitiligo patients and healthy controls and to detect whether this difference was statistically significant. This objective was fulfilled, where our study found that the mean serum level of CXCL13 was (227.35 ± 125.70 ng/L) among the patients, compared to (130.58 ± 26.52 ng/L) among